Ahead of the Global Healthspan Summit, Hevolutio

Startup moves into animal studies of direct cell

Somatic genomics company ‘measures genetic cha

In reality, most people don’t gain a lot b

If you’re prone to holiday blues, here are

Winter is almost here, and with it may come runn

Khosla leads funding round for AI platform that

Mounting evidence indicates that NR may serve as

If you have myasthenia gravis, you may struggle

Melatonin supplements are promoted as affordable

A woman diagnosed with inoperable lung cancer re

A lung cancer advocate shares how to make the mo

Find out how one woman has navigated the emotion

A non-small-cell lung cancer survivor and advoca

Inoperable lung cancer treatment is less likely

Lung cancer isn’t always about smoking.

Innovations for inoperable lung cancer like CT-s

New treatments and traditional therapies can giv

CAROL Bike CEO on the REHIT approach that can di

The “food as medicine” movement says doctors

One woman shares her experience caring for a lov

Smart ring companies to clash in court over alle

Geographic atrophy can be challenging to deal wi

From diagnosis to management, one woman shares h

An expert discusses considerations for HER2-posi

Learn how to share news of your HER2-positive br

Five ways to advocate for yourself and become re

Why taking a proactive approach to longevity mea

Nesta enterprise Challenge Works announces new p

Gene therapy company needs to raise additional €10 million to sustain activities to next milestone. GenSight Biologics, a biopharma specializing in gene therapies for retinal neurodegenerative diseases, has announced the successful confirmation of the second Good Manufacturing Practice (GMP) batch of its lead product candidate LUMEVOQ. This event means the French biotech is now eligible to draw down the €4 million second tranche of a bridge financing agreed with Sofinnova Partners, Invus and UPMC Enterprises. GenSight is developing a pipeline of therapies using mitochondrial targeting sequence and optogenetics technologies to address retinal diseases and central nervous system disorders. The company is currently awaiting the review of its marketing authorization application by the European Medicines Agency for LUMEVOQ, a gene therapy targeting a rare mitochondrial disease leading to irreversible blindness. Before a product like LUMEVOQ can be approved for human use, a validation campaign must be completed, consisting of at least three successful GMP batches manufactured sequentially to demonstrate the robustness, control, consistency and reproducibility of the commercial manufacturing process. Earlier this year, following the successful completion of two batches, shares in GenSight fell dramatically after the third batch had to be terminated due to production issues at its contract development…

For people who have gotten a flu shot heading in

Nutrition and diabetes experts offer tips for de

Managing fatigue is a big part of living with my

What are the new treatments for myasthenia gravi

Highly successful cognitive processing therapy h

Myasthenia gravis finances: What to expect, what

Myasthenia gravis issues: health disparities, qu

A person with myasthenia gravis shares how to ma

Managing triggers is key to living well with mya

What’s it like to live with myasthenia gravis?

Learn tips and strategies from an expert for wha

The Buck Institute’s CEO Eric Verdin on why lo

First International Roundtable will bring togeth

Longevity company builder Maximon’s investment

PREDICTOM is developing an AI screening platform

In an early trial phase, all the people in a stu

LongeVC backs generative AI company that uses Sk

Healthcare firm launches CarePods – AI-powered

Nautilus chief scientist on the power of proteom

Machine learning methods can predict chemical co